Public disclosures

BALL KRISTINE M

Company insiders · Director · Oruka Therapeutics, Inc.

Advertisement
FollowLatest SEC filingSEC filer historyProfile details as reported on 2026-11-13.Following & alerts
Reported transaction lines
8
Buy lines
0
Sell lines
6

Filing activity by month

Original filing lines in up to 12 months with activity.

  • 2026-118

Frequently disclosed stocks

Disclosure history

More filters
Clear filters
Reporting investorSecurityActivityTransaction / periodFiledReported amountSource
BALL KRISTINE M

Director · Oruka Therapeutics, Inc.

ORKA

Oruka Therapeutics, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Stock Option (Right to Buy) · Derivative security · Direct ownership · Reported balance after transaction: 53426 · The option vests as to 1/4 of the underlying shares on May 7, 2025 and as to 1/48 of the underlying shares monthly from May 7, 2025.

2026-11-122026-11-13

18,000 shares/units

SEC 4
BALL KRISTINE M

Director · Oruka Therapeutics, Inc.

ORKA

Oruka Therapeutics, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 0 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.97 to $107.00, inclusive.

2026-11-122026-11-13

≈ $21,397.00

200 shares/units

SEC 4
BALL KRISTINE M

Director · Oruka Therapeutics, Inc.

ORKA

Oruka Therapeutics, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 200 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.76 to $106.46, inclusive.

2026-11-122026-11-13

≈ $265,130.00

2,500 shares/units

SEC 4
BALL KRISTINE M

Director · Oruka Therapeutics, Inc.

ORKA

Oruka Therapeutics, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 2700 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.76 to $105.75, inclusive.

2026-11-122026-11-13

≈ $1,133,706.29

10,765 shares/units

SEC 4
BALL KRISTINE M

Director · Oruka Therapeutics, Inc.

ORKA

Oruka Therapeutics, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 13465 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.69 to $104.65, inclusive.

2026-11-122026-11-13

≈ $212,386.73

2,039 shares/units

SEC 4
BALL KRISTINE M

Director · Oruka Therapeutics, Inc.

ORKA

Oruka Therapeutics, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 15504 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.66 to $103.65, inclusive.

2026-11-122026-11-13

≈ $134,021.16

1,300 shares/units

SEC 4
BALL KRISTINE M

Director · Oruka Therapeutics, Inc.

ORKA

Oruka Therapeutics, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 16804 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.62 to $102.61, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6) and (7) to this Form 4.

2026-11-122026-11-13

≈ $122,107.65

1,196 shares/units

SEC 4
BALL KRISTINE M

Director · Oruka Therapeutics, Inc.

ORKA

Oruka Therapeutics, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Direct ownership · Reported balance after transaction: 18000

2026-11-122026-11-13

18,000 shares/units

SEC 4

Counts describe original filing lines in BriefStock’s coverage. Later amendments can correct or supplement them. Check the original filing for ownership and transaction details.

Advertisement